EP2764111A2 - Microorganismes et procédés de production d'acrylate et autres produits à l'aide d'homosérine - Google Patents

Microorganismes et procédés de production d'acrylate et autres produits à l'aide d'homosérine

Info

Publication number
EP2764111A2
EP2764111A2 EP12780579.4A EP12780579A EP2764111A2 EP 2764111 A2 EP2764111 A2 EP 2764111A2 EP 12780579 A EP12780579 A EP 12780579A EP 2764111 A2 EP2764111 A2 EP 2764111A2
Authority
EP
European Patent Office
Prior art keywords
coa
seq
amino acid
set out
hydroxypropionyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12780579.4A
Other languages
German (de)
English (en)
Inventor
Jun Xu
Charles Winston Saunders
Phillip Richard Green
Juan Esteban VELASQUEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP2764111A2 publication Critical patent/EP2764111A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52—Propionic acid; Butyric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/32—Nucleotides having a condensed ring system containing a six-membered ring having two N-atoms in the same ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C12P7/625—Polyesters of hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
    • C12Y102/04002—Oxoglutarate dehydrogenase (succinyl-transferring) (1.2.4.2), i.e. alpha-ketoglutarat dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01005—L-Amino-acid dehydrogenase (1.4.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03003—D-Amino-acid oxidase (1.4.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01072—Branched-chain-2-oxoacid decarboxylase (4.1.1.72)

Definitions

  • This invention relates to microorganisms that convert a carbon source to acrylate or other desirable products using homoserine and 2-keto-4-hydroxybutyrate as intermediates.
  • the invention provides genetically engineered microorganisms that carry out the conversion, as well as methods for producing acrylate by culturing the microorganisms. Also provided are microorganisms and methods for converting homoserine to 3-hydroxypropionyl-CoA, 3- hydroxypropionate (3HP), poly-3-hydroxypropionate and 1,3-propanediol.
  • Acrylic acid (IUPAC: prop-2-enoic acid) is the simplest unsaturated carboxylic acid.
  • acrylic acid is made from propene.
  • Propene itself is a byproduct of oil refining from petroleum (i.e. , crude oil) and of natural gas production.
  • petroleum i.e. , crude oil
  • Disadvantages associated with traditional acrylic acid production are that petroleum is a nonrenewable starting material and that the oil refining process pollutes the environment.
  • Synthesis methods for acrylic acid utilizing other starting materials have not been adopted for widespread use due to expense or environmental concerns. These starting materials included, for example, acetylene, ethenone and ethylene cyanohydrins.
  • 2011/0125118 relates to using synthesis gas components as a carbon source in a microbial system to produce 3-hydroxypropionic acid, with subsequent conversion of the 3-hydroxyproprionic acid to acrylic acid. Methods to manufacture other organic chemicals in genetically engineered
  • Homoserine is an intermediate in the biosynthesis of the amino acids threonine and methionine. Homoserine is naturally made from glucose in the bacterium E. coli and many other organisms.
  • Figure 1 set out an illustration of the steps converting glucose to homoserine.
  • the present invention utilizes homoserine and 2-keto-4-hydroxybutyrate as intermediates to make acrylate (the chemical form of acrylic acid at neutral pH) and other products of interest.
  • Figures 2 and 3 set out examples of contemplated pathways for making acrylate, 3- hydroxypropionate, poly-3-hydroxypropionate, 1,3-propanediol and 3-hydroxypropionyl-CoA from homoserine.
  • Microorganisms do not naturally make acrylate and the other products, but microorganisms (such as bacteria, yeast, fungi and algae) are genetically modified according to the invention to carry out the conversions in the pathways.
  • Microorganisms include, but are not limited to, an E. coli bacterium.
  • the invention provides a first type of microorganism, one that converts homoserine to acrylate, wherein the microorganism expresses recombinant genes encoding a deaminase or transaminase; a dehydrogenase or decarboxylase; a dehydratase; and a thioesterase, a phosphate transferase/kinase combination, or an acyl-CoA transferase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase aminotransferase, an L-aspartate:2-oxoglutarate aminotransferase, and an L-alanine:2- oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12.
  • Exemplary DNA sequences encoding those aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are respectively set out in SEQ ID NOs: 17 and 19.
  • the dehydrogenase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxypropionyl-CoA.
  • the dehydrogenase is a 2-keto acid
  • Dehydrogenases include, but are not limited to, a pyruvate dehydrogenase, a 2-keto-glutarate dehydrogenase or a branched chain keto acid dehydrogenase.
  • a pyruvate dehydrogenase known in the art is the pyruvate dehydrogenase PDH, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 30, 32 and 34. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 29, 31 and 33.
  • a 2-keto-glutarate dehydrogenase known in the art similarly comprises three subunits, the amino acid sequences of which are set out in SEQ ID NOs: 36, 38 and 40.
  • Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 35, 37 and 39.
  • a branched chain keto acid dehydrogenase known in the art is the branched chain keto acid dehydrogenase BKD, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 22, 24, 26 and 28.
  • Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 21, 23, 25 and 27.
  • the dehydratase catalyzes a reaction to convert 3-hydroxypropionyl-CoA to acryloyl- CoA.
  • the dehydratase is a 3-hydroxypropionyl-CoA-dehydratase.
  • the amino acid sequence of a 3-hydroxypropionyl-CoA-dehydratase known in the art is set out in SEQ ID NO: 48.
  • An exemplary DNA sequence encoding the 3-hydroxypropionyl-CoA- dehydratase is set out in SEQ ID NO: 47.
  • the thioesterase, the phosphate transferase/kinase combination or the acyl-CoA transferase catalyzes a reaction to convert acryloyl-CoA to acrylate.
  • the thioesterase is acryloyl-CoA thioesterase.
  • acryloyltransferase known in the art is set out in SEQ ID NO: 50.
  • An exemplary DNA sequence encoding the phosphate acryloyltransferase is SEQ ID NO: 49.
  • the amino acid sequence of an acrylate kinase known in the art is set out in SEQ ID NO: 52.
  • An exemplary DNA sequence encoding the acrylate kinase is set out in SEQ ID NO: 51.
  • the amino acid sequence of an acyl- CoA transferase known in the art is set out in SEQ ID NO: 46.
  • An exemplary DNA sequence encoding the acyl-CoA transferase is set out in SEQ ID NO: 45.
  • the invention provides a first type of method, one for producing acrylate in which the first type of microorganism is cultured to produce acrylate.
  • the first type of method for producing acrylate converts homoserine to 2-keto-4-hydroxybutyrate, 2-keto-4- hydroxybutyrate to 3-hydroxypropionyl-CoA, 3-hydroxypropionyl-CoA to acryloyl-CoA and then acryloyl-CoA to acrylate.
  • the invention provides a second type of microorganism, one that converts homoserine to acrylate, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a decarboxylase, a dehydrogenase, a dehydratase and a thioesterase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in SEQ ID NOs: 13 and 15.
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the decarboxylase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxy-propionaldehyde.
  • the decarboxylase is a 2-keto acid
  • the 2-keto acid decarboxylases include, but are not limited to, the 2-keto acid decarboxylase KdcA set out in SEQ ID NO: 54 and its derivatives.
  • An exemplary DNA sequence encoding KdcA is set out in SEQ ID NO: 53.
  • the dehydrogenase catalyzes a reaction to convert 3-hydroxy-propionaldehyde to 3- hydroxypropionyl-CoA.
  • the dehydrogenase is a propionaldehyde dehydrogenase.
  • Propionaldehyde dehydrogenases include, but are not limited to, a PduP.
  • Amino acid sequences of some PduP propionaldehyde dehydrogenases known in the art are set out in SEQ ID NOs: 60 and 62.
  • Exemplary DNA sequences encoding the PduP propionaldehyde dehydrogenases are respectively set out in SEQ ID NOs: 59 and 61.
  • the dehydratase catalyzes a reaction to convert 3-hydroxypropionyl-CoA to acryloyl- CoA.
  • the dehydratase is a 3-hydroxypropionyl-CoA dehydratase.
  • the amino acid sequence of 3-hydroxypropionyl-CoA dehydratase known in the art is set out in SEQ ID NO: 48.
  • An exemplary DNA sequence encoding the 3-hydroxypropionyl-CoA dehydratase is set out in SEQ ID NO: 47.
  • the thioesterase catalyzes a reaction to convert acryloyl-CoA to acrylate.
  • the thioesterase is an acryloyl-CoA thioesterase.
  • Acryloyl-CoA thioesterases include, but are not limited to E. coli TesB set out in SEQ ID NO: 90, the Clostridium propionicum-deriyed thioesterase including an E324D substitution set out in SEQ ID NO: 92 and the Megasphaera elsdenii-deriyed thioesterase including an E325D substitution set out in SEQ ID NO: 94.
  • Exemplary DNA sequences encoding these acryloyl-CoA thioesterases are respectively set out in SEQ ID NOs: 89, 91 (codon-optimized for E. coli) and 93 (codon- optimized for E. coli).
  • the invention provides a second type of method, one for producing acrylate in which the second type of microorganism is cultured to produce acrylate.
  • the second type of method for producing acrylate converts homoserine to 2-keto-4-hydroxybutyrate, 2-keto- 4-hydroxybutyrate to 3-hydroxy-propionaldehyde, 3-hydroxy-propionaldehyde to 3- hydroxypropionyl-CoA, 3-hydroxy-propionyl-CoA to acryloyl-CoA and then acryloyl-CoA to acrylate.
  • the invention provides a third type of microorganism, one that converts homoserine to 3-hydroxypropionate, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a dehydrogenase or decarboxylase, and acyl-CoA transferase or athioesterase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the dehydrogenase or decarboxylase catalyzes a reaction to convert 2-keto-4- hydroxybutyrate to 3-hydroxypropionyl-CoA.
  • the dehydrogenase is a 2- keto acid dehydrogenase (or an alpha keto acid dehydrogenase).
  • Dehydrogenases include, but are not limited to, a pyruvate dehydrogenase, a 2-keto-glutarate dehydrogenase or a branched chain keto acid dehydrogenase.
  • a pyruvate dehydrogenase known in the art is the pyruvate dehydrogenase PDH, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 30, 32 and 34. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 29, 31 and 33.
  • a 2-keto-glutarate dehydrogenase known in the art similarly comprises three subunits, the amino acid sequences of which are set out in SEQ ID NOs: 36, 38 and 40. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 35, 37 and 39.
  • a branched chain keto acid dehydrogenase known in the art is the branched chain keto acid dehydrogenase BKD, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 22, 24, 26 and 28. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 21, 23, 25 and 27.
  • the acyl-CoA transferase or the acyl-CoA thioesterase catalyzes a reaction to convert 3- hydroxypropionyl-CoA to 3-hydroxypropionate.
  • Contemplated thioesterases include, but are not limited to E. coli TesB set out in SEQ ID NO: 90, the C. propionicum-dewed thioesterase including an E324D substitution set out in SEQ ID NO: 92 and the M. elsdenii-dewed thioesterase including an E325D substitution set out in SEQ ID NO: 94.
  • Exemplary (codon- optimized for E. coli) DNA sequences encoding these thioesterases are respectively set out in SEQ ID NOs: 89, 91(codon-optimized for E. coli) and 93 (codon-optimized for E. coli).
  • the invention provides a third type of method, one for producing 3- hydroxypropionate in which the third type of microorganism is cultured to produce 3- hydroxypropionate .
  • the third type of method converts homoserine to 2-keto-4-hydroxybutyrate, 2-keto-4-hydroxybutyrate to 3-hydroxy-propionaldehyde,3-hydroxy-propionaldehyde to 3- hydroxypropionyl-CoA and then 3-hydroxypropionyl-CoA to 3-hydroxypropionate.
  • the invention provides a fourth type of microorganism, one that converts homoserine to 3-hydroxypropionate, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a decarboxylase and a dehydrogenase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the decarboxylase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxy-propionaldehyde.
  • the decarboxylase is a 2-keto acid
  • the 2-keto acid decarboxylases include, but are not limited to, the 2-keto acid decarboxylase KdcA set out in SEQ ID NO: 54 and its derivatives.
  • An exemplary DNA sequence encoding KdcA is set out in SEQ ID NO: 53.
  • the dehydrogenase catalyzes a reaction to convert 3 -hydroxy-propionaldehyde to 3- hydroxypropionate.
  • the dehydrogenase is an aldehyde dehydrogenase.
  • Amino acid sequences of aldehyde dehydrogenases known in the art are set out in SEQ ID NOs: 56 and 58.
  • Exemplary DNA sequences encoding the aldehyde dehydrogenases are respectively set out in SEQ ID NOs: 55 and 57.
  • the invention provides a fourth type of method, one for producing 3- hydroxypropionate in which the fourth type of microorganism is cultured to produce 3- hydroxypropionate .
  • the fourth type of method converts homoserine to 2-keto-4- hydroxybutyrate, 2-keto-4-hydroxybutyrate to 3-hydroxy-propionaldehyde, 3-hydroxy- propionaldehyde to 3-hydroxypropionate.
  • the invention provides a fifth type of microorganism, one that converts homoserine to 3-hydroxypropionate, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a decarboxylase, a dehydrogenase, and a acyl-CoA transferase or a thioesterase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in SEQ ID NOs: 13 and 15.
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the decarboxylase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxy-propionaldehyde.
  • the decarboxylase is a 2-keto acid
  • the 2-keto acid decarboxylases include, but are not limited to, the 2-keto acid decarboxylase KdcA set out in SEQ ID NO: 54 and its derivatives.
  • An exemplary DNA sequence encoding KdcA is set out in SEQ ID NO: 53.
  • the dehydrogenase catalyzes a reaction to convert 3-hydroxy-propionaldehyde to 3- hydroxypropionyl-CoA.
  • the dehydrogenase is a propionaldehyde dehydrogenase.
  • Propionaldehyde dehydrogenases include, but are not limited to, a PduP. Amino acid sequences of some PduP propionaldehyde dehydrogenases known in the art are set out in SEQ ID NOs: 60 and 62. Exemplary DNA sequences encoding the PduP propionaldehyde dehydrogenases are respectively set out in SEQ ID NOs: 59 and 61.
  • the 3-hydroxypropionyl-CoA transferase or thioesterase catalyzes a reaction to convert 3-hydroxypropionyl-CoA to 3-hydroxypropionate.
  • Contemplated thioesterases include, but are not limited to E. coli TesB set out in SEQ ID NO: 90, the C. propionicum-deriyed thioesterase including an E324D substitution set out in SEQ ID NO: 92 and the M. elsdenii-deriyed thioesterase including an E325D substitution set out in SEQ ID NO: 94.
  • Exemplary DNA sequences encoding these acryloyl-CoA thioesterases are respectively set out in SEQ ID NOs: 89, 91 (codon-optimized for E. coli) and 93 (codon-optimized for E. coli).
  • the invention provides a fifth type of method, one for producing 3- hydroxypropionate in which the fifth type of microorganism is cultured to produce 3- hydroxypropionate.
  • the fifth type of method for producing acrylate converts homoserine to 2- keto-4-hydroxybutyrate, 2-keto-4-hydroxybutyrate to 3-hydroxy-propionaldehyde, 3-hydroxy- propionaldehyde to 3-hydroxypropionyl-CoA, and 3-hydroxy-propionyl-CoA to 3- hydroxypropionate .
  • the invention provides a sixth type of microorganism, one that converts homoserine to poly-3-hydroxypropionate, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a dehydrogenase or decarboxylase, and a PHA synthase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in SEQ ID NOs: 13 and 15.
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the dehydrogenase or decarboxylase catalyzes a reaction to convert 2-keto-4- hydroxybutyrate to 3-hydroxypropionyl-CoA.
  • the dehydrogenase is a 2- keto acid dehydrogenase (or an alpha keto acid dehydrogenase).
  • Dehydrogenases include, but are not limited to, a pyruvate dehydrogenase, a 2-keto-glutarate dehydrogenase or a branched chain keto acid dehydrogenase.
  • a pyruvate dehydrogenase known in the art is the pyruvate dehydrogenase PDH, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 30, 32 and 34. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 29, 31 and 33.
  • a 2-keto-glutarate dehydrogenase known in the art similarly comprises three subunits, the amino acid sequences of which are set out in SEQ ID NOs: 36, 38 and 40. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 35, 37 and 39.
  • a branched chain keto acid dehydrogenase known in the art is the branched chain keto acid dehydrogenase BKD, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 22, 24, 26 and 28. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 21, 23, 25 and 27.
  • the PHA synthase catalyzes a reaction to convert 3-hydroxypropionyl-CoA to poly-Shy droxyalkanoate containing 3-hydroxypropionate monomers.
  • the polymer may have a molecule of Coenzyme A (CoA) at the carboxy end.
  • CoA Coenzyme A
  • the amino acid sequence of a PHA synthase known in the art is set out in SEQ ID NO: 42.
  • An exemplary DNA sequence encoding the PHA synthase is set out in SEQ ID NO: 41.
  • the invention provides a sixth type of method, one for producing poly- 3-hydroxypropionate in which the sixth type of microorganism is cultured to produce poly-3- hydroxypropionate .
  • the sixth type of method converts homoserine to 2-keto-4-hydroxybutyrate, 2-keto-4-hydroxybutyrate to 3-hydroxypropionyl-CoA and 3-hydroxypropionyl-CoA to poly-Shy droxypropionate .
  • the invention provides a seventh type of microorganism, one that converts homoserine to poly-3-hydroxypropionate, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a decarboxylase, a dehydrogenase and a PHA synthase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the decarboxylase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxy-propionaldehyde.
  • the decarboxylase is a 2-keto acid
  • the 2-keto acid decarboxylases include, but are not limited to, the 2-keto acid decarboxylase KdcA set out in SEQ ID NO: 54 and its derivatives.
  • An exemplary DNA sequence encoding KdcA is set out in SEQ ID NO: 53..
  • the dehydrogenase catalyzes a reaction to convert 3 -hydroxy-propionaldehyde to 3- hydroxypropionyl-CoA.
  • the dehydrogenase is a propionaldehyde dehydrogenase.
  • Propionaldehyde dehydrogenases include, but are not limited to, a PduP. Amino acid sequences encoding of PduP propionaldehyde dehydrogenases known in the art are set out in SEQ ID NOs: 60 and 62. Exemplary DNA sequences encoding the PduP propionaldehyde dehydrogenases are respectively set out in SEQ ID NOs: 59 and 61.
  • the PHA synthase catalyzes a reaction to convert 3-hydroxypropionyl-CoA to poly-Shy droxyalkanoate containing 3-hydroxypropionate monomers.
  • the polymer may have a molecule of Coenzyme A (CoA) at the carboxy end.
  • CoA Coenzyme A
  • the amino acid sequence of a PHA synthase known in the art is set out in SEQ ID NO: 42.
  • An exemplary DNA sequence encoding the PHA synthase is set out in SEQ ID NO: 41.
  • the invention provides a seventh type of method, one for producing poly- 3-hydroxypropionate in which the seventh type of microorganism is cultured to produce poly- 3-hydroxypropionate .
  • the seventh type of method converts homoserine to 2-keto-4- hydroxybutyrate, 2-keto-4-hydroxybutyrate to 3-hydroxy-propionaldehyde, 3-hydroxy- propionaldehyde to 3-hydroxypropionyl-CoA and then 3-hydroxy-propionyl-CoA to poly-3- hydroxypropionate .
  • the invention provides a eighth type of microorganism that converts homoserine to 3-hydroxypropionyl-CoA, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, and a dehydrogenase or decarboxylase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in SEQ ID NOs: 13 and 15.
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the dehydrogenase or decarboxylase catalyzes a reaction to convert 2-keto-4- hydroxybutyrate to 3-hydroxypropionyl-CoA.
  • the dehydrogenase is a 2- keto acid dehydrogenase (or an alpha keto acid dehydrogenase).
  • Dehydrogenases include, but are not limited to, a pyruvate dehydrogenase, a 2-keto-glutarate dehydrogenase or a branched chain keto acid dehydrogenase.
  • a pyruvate dehydrogenase known in the art is the pyruvate dehydrogenase PDH, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 30, 32 and 34. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 29, 31 and 33.
  • a 2-keto-glutarate dehydrogenase known in the art similarly comprises three subunits, the amino acid sequences of which are set out in SEQ ID NOs: 36, 38 and 40. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 35, 37 and 39.
  • a branched chain keto acid dehydrogenase known in the art is the branched chain keto acid dehydrogenase BKD, the amino acid sequences of the subunits of which are set out in SEQ ID NOs: 22, 24, 26 and 28. Exemplary DNA sequences encoding those subunits are respectively set out in SEQ ID NOs: 21, 23, 25 and 27.
  • the invention provides an eighth type of method, one for producing 3-hydroxypropionyl-CoA in which the eighth type of microorganism is cultured to produce 3- hydroxypropionyl-CoA.
  • the eighth type of method converts homoserine to 2-keto-4- hydroxybutyrate and then converts 2-keto-4-hydroxybutyrate to 3-hydroxypropionyl-CoA.
  • the invention provides a ninth type of microorganism, one that converts homoserine to 3-hydroxypropionyl-CoA, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a decarboxylase, and a
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in SEQ ID NOs: 13 and 15.
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the decarboxylase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxy-propionaldehyde.
  • the decarboxylase is a 2-keto acid
  • the 2-keto acid decarboxylases include, but are not limited to, the 2-keto acid decarboxylase KdcA set out in SEQ ID NO: 54 and its derivatives.
  • An exemplary DNA sequence encoding KdcA is set out in SEQ ID NO: 53.
  • the dehydrogenase catalyzes a reaction to convert 3-hydroxy-propionaldehyde to 3- hydroxypropionyl-CoA.
  • the dehydrogenase is a propionaldehyde dehydrogenase.
  • Propionaldehyde dehydrogenases include, but are not limited to, a PduP. Amino acid sequences encoding of PduP propionaldehyde dehydrogenases known in the art are set out in SEQ ID NOs: 60 and 62. Exemplary DNA sequences encoding the PduP propionaldehyde dehydrogenases are respectively set out in SEQ ID NOs: 59 and 61.
  • the invention provides a ninth type of method, one for producing 3-hydroxypropionyl-CoA in which the ninth type of microorganism is cultured to produce 3- hydroxypropionyl-CoA.
  • the ninth type of method converts homoserine to 2-keto-4- hydroxybutyrate, 2-keto-4-hydroxybutyrate to 3-hydroxy-propionaldehyde, and 3-hydroxy- propionaldehyde to 3-hydroxypropionyl-CoA.
  • the invention provides an tenth type of microorganism, one that converts homoserine to 1,3-propanediol, wherein the microorganism expresses recombinant genes encoding: a deaminase or transaminase, a decarboxylase and a 1,3-propanediol dehydrogenase or aldehyde reductase.
  • the deaminase or transaminase catalyzes a reaction to convert homoserine to 2-keto-4- hydroxybutyrate.
  • the deaminase or transaminase is an aminotransferase, an L-amino acid oxidase or an L-amino acid dehydrogenase.
  • Aminotransferases include, but are not limited to, a glutamate-oxaloacetate aminotransferase, a glutamate-pyruvate
  • aminotransferase an L-aspartate:2-oxoglutarate aminotransferase, an L-alanine:2-oxoglutarate aminotransferase.
  • Amino acid sequences of some aminotransferases known in the art are set out in SEQ ID NOs: 2, 4, 6, 8, 10 and 12. Exemplary DNA sequences encoding those
  • aminotransferases are respectively set out in SEQ ID NOs: 1, 3, 5, 7, 9 and 11.
  • Amino acid sequences of some L-amino acid oxidases known in the art are set out in SEQ ID NOs: 14 and 16.
  • Exemplary DNA sequences encoding those L-amino acid oxidases are respectively set out in SEQ ID NOs: 13 and 15.
  • Amino acid sequences of some L-amino acid dehydrogenases known in the art are set out in SEQ ID NOs: 18 and 20.
  • Exemplary DNA sequences encoding those L- amino acid dehydrogenases are set out in SEQ ID NOs: 17 and 19.
  • the decarboxylase catalyzes a reaction to convert 2-keto-4-hydroxybutyrate to 3- hydroxy-propionaldehyde.
  • the decarboxylase is a 2-keto acid
  • the 2-keto acid decarboxylases include, but are not limited to, the 2-keto acid decarboxylase KdcA set out in SEQ ID NO: 54 and its derivatives.
  • An exemplary DNA sequence encoding KdcA is set out in SEQ ID NO: 53.
  • the 1,3-propanediol dehydrogenase or aldehyde reductase catalyzes a reaction to convert 3-hydroxypropionaldehyde to 1,3-propanediol.
  • Amino acid sequences of some 1,3-propanediol dehydrogenases know in the art are set out in SEQ ID NOs: 64, 66, 68, 70 and 72.
  • Exemplary DNA sequence encoding the 1,3-propanediol dehydrogenases are respectively set out in SEQ ID NOs: 63, 65, 67, 69 and 71.
  • the invention provides an tenth type of method, one for producing 1,3-propanediol in which the tenth type of microorganism is cultured to produce 1,3-propanediol.
  • the tenth type of method converts homoserine to 2-keto-4-hydroxybutyrate, 2-keto-4- hydroxybutyrate to 3-hydroxy-propionaldehyde and then 3-hydroxy-propionaldehyde to 1,3- propanediol.
  • the invention provides microorganisms that include further genetic modifications in order to increase the carbon flow to homoserine which, in turn, increases the production of acrylate or other products of the invention.
  • the microorganisms exhibit one or more of the following characteristics.
  • the microorganism exhibits increased carbon flow to oxaloacetate in comparison to a corresponding wild-type microorganism.
  • the microorganism expresses a recombinant gene encoding, for example, phosphoenolpyruvate carboxylase or pyruvate carboxylase (or both).
  • the phosphoenolpyruvate caroxylases include, but are not limited to, the phosphoenolpyruvate carboxylase set out in SEQ ID NO: 84.
  • An exemplary DNA sequence encoding the phosphoenolpyruvate carboxylase is set out in SEQ ID NO: 83.
  • the pyruvate carboxylases include, but are not limited to, the pyruvate carboxylases set out in SEQ ID NOs: 86 and 88.
  • Exemplary DNA sequences encoding the pyruvate carboxylases are set out in SEQ ID NO: 85 and 87.
  • the microorganism exhibits reduced aspartate kinase feedback inhibition in comparison to a corresponding wild-type microorganism.
  • the microorganism expresses one or more of the genes encoding the polypeptides including, but not limited to, S345F ThrA (SEQ ID NO: 76), T352I LysC (SEQ ID NO: 78) and MetL (SEQ ID NO: 74).
  • Exemplary coding sequences encoding the polypeptides are respectively set out in SEQ ID NO: 75, SEQ ID NO: 77 and SEQ ID NO: 73.
  • the microorganism exhibits reduced lysA gene expression or diaminopimelate decarboxylase activity in comparison to a corresponding wild-type
  • the microorganism exhibits reduced dapA expression or dihydropicolinate synthase activity in comparison to a corresponding wild type organism.
  • An exemplary DNA sequence of a lysA coding sequence known in the art is set out in SEQ ID NO: 113. It encodes the amino acid sequence set out in SEQ ID NO: 114.
  • An exemplary DNA sequence of a dap A coding sequence known in the art is set out in SEQ ID NO: 115. It encodes the amino acid sequence set out in SEQ ID NO: 116.
  • the microorganism exhibits reduced metA gene expression or homoserine succinyltransferase activity in comparison to a corresponding wild-type
  • An exemplary DNA sequence of a metA coding sequence known in the art is set out in SEQ ID NO: 79. It encodes the amino acid sequence set out in SEQ ID NO: 80.
  • the microorganism exhibits reduced thrB gene expression or homoserine kinase activity in comparison to a corresponding wild-type microorganism.
  • An exemplary DNA sequence of a thrB coding sequence known in the art is set out in SEQ ID NO: 81. It encodes the amino acid sequence set out in SEQ ID NO: 82.
  • the microorganism does not express an eda gene.
  • An exemplary DNA sequence of an eda coding sequence known in the art is set out in SEQ ID NO: 43. It encodes the amino acid sequence set out in SEQ ID NO: 44.
  • the invention provides an methods of culturing the further modified microorganisms to produce products of the invention.
  • the invention provides a thioesterase that hydrolyzes an intermediate of a metabolic pathway described herein to produce a desired end product.
  • a microorganism of the invention expresses a recombinant gene comprising a nucleic acid sequence encoding a thioesterase with activity against Coenzyme A (Co A) attached to a two-, three- or four-carbon chain, such as a three- or four-carbon chain comprising a double bond (e.g. , a three- or four-carbon chain comprising a double bond between C2 and C3).
  • the thioesterase hydrolyzes acryloyl-CoA to form acrylic acid.
  • the thioesterase hydrolyzes crotonoyl-CoA to form crotonic acid.
  • This aspect of the invention is predicated, at least in part, on the use of thioesterases with activity against substrates with short carbon chains (e.g., less than four carbons in the main chain) comprising double bonds. While thioesterases have been identified that hydrolyze saturated short carbon chains, it would not have been expected that the identified thioesterases would act upon an unsaturated carbon chain. Thioesterases would be expected to exhibit a high degree of substrate specificity with respect to short carbon chains to avoid hydrolysis of acetyl-CoA, which is critical to fatty synthesis. Unexpectedly, thioesterases that hydrolyze CoA intermediates attached to short, unsaturated carbon chains were identified and successfully produced (or overproduced) in host cells.
  • Exemplary thioesterases include, but are not limited to, TesB from E. coli and homologs thereof from different organisms.
  • the host cell optionally comprises a
  • polynucleotide comprising a nucleic acid sequence encoding an amino acid sequence at least 80% identical (e.g., 85%, 90%, 95%, 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 90 (TesB), and encoding a polypeptide having thioesterase activity (i.e., the polypeptide hydrolyzes thioesters bonds).
  • TesB amino acid sequence set out in SEQ ID NO: 89.
  • the amino acid sequences of other known thioesterases are set out in SEQ ID NO: 96, 98, 100, 102, 104, 106 and 108.
  • Exemplary codon- optimized (for E.coli) DNA sequences encoding the thioesterases are respectively set out in SEQ ID NOs: 95, 97, 99, 101, 103, 105 and 107.
  • Engineered thioesterases also are appropriate for use in the invention.
  • mutation(s) within the active site of a CoA transferase confers thioesterase activity to the enzyme while substantially reducing (if not eliminating) transferase activity.
  • Use of a thioesterase is, in various aspects, superior to use of a CoA transferase by releasing energy associated with the CoA bond. The energy release drives the acrylic acid or crotonic acid pathway to completion.
  • An exemplary method of modifying a CoA transferase to obtain thioesterase activity comprises substituting the amino acid serving as the catalytic carboxylate with an alternate amino acid.
  • CoA transferases suitable for modification and use in the context of the invention include, but are not limited to, acetyl-CoA transferases, propionyl-CoA transferases, and butyryl-CoA
  • the thioesterase of the invention comprises the amino acid sequence of a propionyl-CoA transferase wherein the catalytic glutamate residue is replaced with an alternate amino acid, such as aspartate.
  • exemplary propionyl-CoA transferases suitable for mutation include propionyl-CoA transferases from C. propionicum and M. elsdenii.
  • Glutamate residue 324 and glutamate residue 325 are the catalytic carboxylates in C. propionicum propionyl-CoA transferase and M. elsdenii propionyl-CoA transferase, respectively.
  • the catalytic amino acid residue in propionate CoA transferases from other sources is identified by sequence alignment with, e.g., the amino acid sequence of C. propionicum propionyl-CoA transferase.
  • the catalytic amino acid residue in other CoA transferases is identified by sequence alignment with, e.g., the amino acid sequence of C.
  • propionicum propionyl-CoA transferase is an example of a sequence suitable for comparison with other CoA transferases; it will be appreciated that sequences of other CoA transferase sequences can be compared to identify the conserved glutamate catalytic residue for mutation. It will also be appreciated that mutated CoA transferase having thioesterase activity can be generated by altering the nucleic acid sequence of an existing CoA transferase-encoding polynucleotide, or by generating a new polynucleotide based on the coding sequence of a CoA transferase.
  • the host cell of the invention comprises a polynucleotide comprising a nucleic acid sequence encoding an amino acid sequence at least 80% identical (e.g., 85%, 90%, 95%, 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 92 (C. propionicum-denved thioesterase including an E324D substitution) or SEQ ID NO: 94 (M. elsdenii-deriyed thioesterase including an E325D substitution) and encoding a polypeptide having thioesterase activity.
  • Exemplary codon- optimized for E.
  • DNA sequences encoding the two thioesterases are respectively set out in SEQ ID NOs: 91 and 93.
  • Amino acid sequences of other engineered thioesterases are set out in SEQ ID NOs: 109, 110, 111 and 112.
  • isolated enzymes can be used to catalyze one or more steps described in the aspects of the invention.
  • Advantages may include higher product yields, easier product recovery from a more concentrated solution without cell related impurities, a greater range of possible reaction conditions the use of less expensive reactors.
  • Figure 1 shows steps in the conversion of glucose to homoserine.
  • Figure 2 shows steps in methods of the invention for producing acrylate, 3- hydroxypropionyl-CoA, 3-hydroxypropionate and poly-3-hydroxypropionate from homoserine.
  • Figure 3 shows steps in methods of the invention for producing acrylate, 3- hydroxypropionate, 1 ,3 -propanediol and 3-hydroxypropionyl-CoA from homoserine.
  • Figure 4 shows single ion monitoring (SIM) LC-MS chromatograms of 2-keto-4- hydroxybutyrate and glutamate, after incubation of L-homoserine and a-ketoglutarate with (reaction) or without (control) Pf_AT aminotransferase.
  • SIM single ion monitoring
  • Figure 5 show initial rates of deamination as a function of L-homoserine concentration by Pf LAT aminotransferase.
  • Figure 6 shows the production of 3-hydroxypropionyl-CoA from L-homoserine catalyzed by D-amino acid oxidase and 2-ketoglutarate dehydrogenase or D-amino acid oxidase, KdcA decarboxylase, and PduP dehydrogenase.
  • Figure 7 shows HPLC chromatograms of samples of acryloyl-CoA after incubation with (top) or without (bottom) a dehydratase, evidencing the formation of 3-hydroxypropionyl-CoA only when the enzyme was present.
  • Figure 8 shows the production 3-hydroxypropionyl-CoA from acryloyl-CoA catalyzed by a dehydratase.
  • Figure 9 shows the consumption of 3-hydroxypropionyl-CoA after incubation with PHA synthase suggesting the formation of the poly(3-hydroxypropionate).
  • Figure 10 shows thioesterase activity against an acryloyl-CoA substrate. Activity is monitored by optical density (OD) at 412 nm.
  • OD optical density
  • Figure 11 shows thioesterase activity against an octanoyl-CoA substrate. Activity is monitored by optical density (OD) at 412 nm.
  • OD optical density
  • Figure 12 shows thioesterase activity against an acryloyl-CoA substrate. Activity is monitored by optical density (OD) at 412 nm.
  • OD optical density
  • Figure 13 shows thioesterase activity against an acryloyl-CoA substrate. Activity is monitored by optical density (OD) at 412 nm.
  • OD optical density
  • Figure 14 shows thioesterase activity against an octanoyl-CoA substrate. Activity is monitored by optical density (OD) at 412 nm.
  • OD optical density
  • Figure 15 shows thioesterase activity against an octanoyl-CoA substrate. Activity is monitored by optical density (OD) at 412 nm.
  • OD optical density
  • the invention provides the products acrylic acid and acrylate.
  • acrylate is the carboxylate anion (i. e., conjugate base) of acrylic acid.
  • Ka is the acid dissociation constant of acrylic acid.
  • the pKa of acrylic acid in water is about 4.35.
  • acrylic acid will exist primarily as the carboxylate anion.
  • "acrylic acid” and “acrylate” are both meant to encompass the other.
  • amplify refers to any process or protocol for copying a polynucleotide sequence into a larger number of polynucleotide molecules, e.g., by reverse transcription, polymerase chain reaction, and ligase chain reaction.
  • an antisense sequence refers to a sequence that specifically hybridizes with a second polynucleotide sequence.
  • an antisense sequence is a DNA sequence that is inverted relative to its normal orientation for transcription.
  • Antisense sequences can express an RNA transcript that is complementary to a target mRNA molecule expressed within the host cell (e.g., it can hybridize to target mRNA molecule through Watson-Crick base pairing).
  • cDNA refers to a DNA that is complementary or identical to an mRNA, in either single stranded or double stranded form.
  • complementary refers to a polynucleotide that base pairs with a second polynucleotide. Put another way, “complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, a polynucleotide having the sequence 5 '-GTCCGA-3' is complementary to a polynucleotide with the sequence 5 '-TCGGAC-3' .
  • a "conservative substitution” refers to the substitution in a polypeptide of an amino acid with a functionally similar amino acid. Put another way, a conservative substitution involves replacement of an amino acid residue with an amino acid residue having a similar side chain.
  • Families of amino acid residues having similar side chains have been defined within the art, and include amino acids with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), beta-branched side chains (e.g., threonine, valine, and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine).
  • basic side chains e.g., lysine, arginine, and histidine
  • acidic side chains
  • a "corresponding wild-type microorganism" is the naturally-occurring microorganism that would be the same as the microorganism of the invention except that the naturally-occurring microorganism has not been genetically engineered to express any recombinant genes.
  • nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
  • endogenous refers to polynucleotides, polypeptides, or other compounds that are expressed naturally or originate within an organism or cell. That is, endogenous polynucleotides, polypeptides, or other compounds are not exogenous. For instance, an "endogenous" polynucleotide or peptide is present in the cell when the cell was originally isolated from nature.
  • expression vector refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed.
  • suitable expression vectors can be an autonomously replicating plasmid or integrated into the chromosome.
  • exogenous refers to any polynucleotide or polypeptide that is not naturally found or expressed in the particular cell or organism where expression is desired.
  • Exogenous polynucleotides, polypeptides, or other compounds are not endogenous.
  • homoserine includes enantiomers such as L-homoserine and D- homoserine.
  • hybridization includes any process by which a strand of a nucleic acid joins with a complementary nucleic acid strand through base-pairing. Thus, the term refers to the ability of the complement of the target sequence to bind to a test (i.e. , target) sequence, or vice-versa.
  • hybridization conditions are typically classified by degree of “stringency” of the conditions under which hybridization is measured. The degree of stringency can be based, for example, on the melting temperature (Tm) of the nucleic acid binding complex or probe. For example, “maximum stringency” typically occurs at about Tm -5° C.
  • 0.5xSSC high stringency. Functionally, maximum stringency conditions may be used to identify nucleic acid sequences having strict (i.e. , about 100%) identity or near-strict identity with the hybridization probe; while high stringency conditions are used to identify nucleic acid sequences having about 80% or more sequence identity with the probe.
  • nucleotide or percent “identity,” in the context of two or more polynucleotide or polypeptide sequences, refers to two or more sequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using sequence comparison algorithms or by visual inspection.
  • Microorganisms of the invention expressing recombinant genes are not naturally- occurring.
  • the microorganisms are man-made and have been genetically engineered to express recombinant genes.
  • the microorganisms of the invention have been genetically engineered to express the recombinant genes encoding the enzymes necessary to carry out the conversion of homoserine to the desired product.
  • Microorganisms of the invention are bacteria, yeast, fungi or algae. Bacteria include, but not limited to, E. coli strains K, B or C. Microorganisms that are more resistant to toxicity of the products of the invention are preferred.
  • Plant cells that are not naturally-occurring (are man-made) and have been genetically engineered to express recombinant genes carrying out the conversions detailed herein are contemplated by the invention to be alternative cells to microorganisms, for example in the production of poly-Shy droxypropionate .
  • naturally-occurring refers to an object that can be found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.
  • naturally-occurring and “wild-type” are synonyms.
  • operably linked when describing the relationship between two DNA regions or two polypeptide regions, means that the regions are functionally related to each other.
  • a promoter is operably linked to a coding sequence if it controls the transcription of the sequence
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation
  • a sequence is operably linked to a peptide if it functions as a signal sequence, such as by participating in the secretion of the mature form of the protein.
  • a recombinant gene that is "over-expressed” produces more RNA and/or protein than a corresponding naturally-occurring gene in the microorganism. Methods of measuring amounts of RNA and protein are known in the art. Over-expression can also be determined by measuring protein activity such as enzyme activity. Depending on the embodiment of the invention, "over-expression" is an amount at least 3%, at least 5%, at least 10%, at least 20%, at least 25%, or at least 50% more.
  • An over-expressed polynucleotide is generally a polynucleotide native to the host cell, the product of which is generated in a greater amount than that normally found in the host cell. Over-expression is achieved by, for instance and without limitation, operably linking the polynucleotide to a different promoter than the polynucleotide's native promoter or introducing additional copies of the polynucleotide into the host cell.
  • polynucleotide refers to a polymer composed of nucleotides.
  • the polynucleotide may be in the form of a separate fragment or as a component of a larger nucleotide sequence construct, which has been derived from a nucleotide sequence isolated at least once in a quantity or concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard molecular biology methods, for example, using a cloning vector.
  • a nucleotide sequence is represented by a DNA sequence (i.e. , A, T, G, C), this also includes an RNA sequence (i.e.
  • polynucleotide refers to a polymer of nucleotides removed from other nucleotides (a separate fragment or entity) or can be a component or element of a larger nucleotide construct, such as an expression vector or a polycistronic sequence. Polynucleotides include DNA, RNA and cDNA sequences.
  • polypeptide refers to a polymer composed of amino acid residues which may or may not contain modifications such as phosphates and formyl groups.
  • primer refers to a polynucleotide that is capable of specifically hybridizing to a designated polynucleotide template and providing a point of initiation for synthesis of a complementary polynucleotide when the polynucleotide primer is placed under conditions in which synthesis is induced.
  • recombinant polynucleotide refers to a polynucleotide having sequences that are not joined together in nature.
  • a recombinant polynucleotide may be included in a suitable vector, and the vector can be used to transform a suitable host cell.
  • a host cell that comprises the recombinant polynucleotide is referred to as a "recombinant host cell.”
  • the polynucleotide is then expressed in the recombinant host cell to produce, e.g., a "recombinant polypeptide.”
  • recombinant expression vector refers to a DNA construct used to express a polynucleotide that, e.g., encodes a desired polypeptide.
  • a recombinant expression vector can include, for example, a transcriptional subunit comprising (i) an assembly of genetic elements having a regulatory role in gene expression, for example, promoters and enhancers, (ii) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (iii) appropriate transcription and translation initiation and termination sequences.
  • Recombinant expression vectors are constructed in any suitable manner. The nature of the vector is not critical, and any vector may be used, including plasmid, virus, bacteriophage, and transposon.
  • Possible vectors for use in the invention include, but are not limited to, chromosomal, nonchromosomal and synthetic DNA sequences, e.g., bacterial plasmids; phage DNA; yeast plasmids; and vectors derived from combinations of plasmids and phage DNA, DNA from viruses such as vaccinia, adenovirus, fowl pox, baculovirus, SV40, and pseudorabies.
  • viruses such as vaccinia, adenovirus, fowl pox, baculovirus, SV40, and pseudorabies.
  • a "recombinant gene” is not a naturally-occurring gene.
  • a recombinant gene is man-made.
  • a recombinant gene includes a protein coding sequence operably linked to expression control sequences.
  • Embodiments include, but are not limited to, an exogenous gene introduced into a microorganism, an endogenous protein coding sequence operably linked to a heterologous promoter (i. e. , a promoter not naturally linked to the protein coding sequence) and a gene with a modified protein coding sequence (e.g. , a protein coding sequence encoding an amino acid change or a protein coding sequence optimized for expression in the microorganism).
  • the recombinant gene is maintained in the genome of the
  • reduced expression is expression of less RNA or protein than the corresponding natural level of expression. Methods of measuring amounts of RNA and protein are known in the art. Reduced expression can also be determined by measuring protein activity such as enzyme activity. Depending on the embodiment of the invention, “reduced” is an amount at least 3%, at least 5%, at least 10%, at least 20%, at least 25%, or at least 50% less.
  • hybridization refers to the binding, duplexing, or hybridizing of a polynucleotide preferentially to a particular nucleotide sequence under stringent conditions.
  • stringent conditions refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences.
  • substantially homologous or “substantially identical” in the context of two nucleic acids or polypeptides, generally refers to two or more sequences or subsequences that have at least 40%, 60%, 80%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using sequence comparison algorithms or by visual inspection.
  • the substantial identity can exist over any suitable region of the sequences, such as, for example, a region that is at least about 50 residues in length, a region that is at least about 100 residues, or a region that is at least about 150 residues.
  • the sequences are substantially identical over the entire length of either or both comparison biopolymers.
  • the polynucleotide(s) encoding one or more enzyme activities for steps in the pathways of the invention may be derived from any source.
  • the polynucleotide is isolated from a natural source such as bacteria, algae, fungi, plants, or animals; produced via a semi-synthetic route (e.g., the nucleic acid sequence of a polynucleotide is codon optimized for expression in a particular host cell, such as E. coli); or synthesized de novo.
  • it is advantageous to select an enzyme from a particular source based on, e.g. , the substrate specificity of the enzyme or the level of enzyme activity in a given host cell.
  • polynucleotide are naturally found in the host cell and over-expression of the polynucleotide is desired.
  • additional copies of the polynucleotide are introduced in the host cell to increase the amount of enzyme.
  • over-expression of an endogenous polynucleotide may be achieved by
  • upregulating endogenous promoter activity or operably linking the polynucleotide to a more robust heterologous promoter.
  • Exogenous enzymes and their corresponding polynucleotides also are suitable for use in the context of the invention, and the features of the biosynthesis pathway or end product can be tailored depending on the particular enzyme used.
  • polynucleotides of the invention may be engineered to include alternative degenerate codons to optimize expression of the polynucleotide in a particular microorganism.
  • a polynucleotide may be engineered to include codons preferred in E. coli if the DNA sequence will be expressed in E. coli. Methods for codon-optimization are known in the art.
  • the microorganism produces an analog or variant of the polypeptide encoding an enzyme activity.
  • Amino acid sequence variants of the polypeptide include substitution, insertion, or deletion variants, and variants may be substantially homologous or substantially identical to the unmodified polypeptides.
  • the variants retain at least some of the biological activity, e.g. , catalytic activity, of the polypeptide.
  • Other variants include variants of the polypeptide that retain at least about 50%, preferably at least about 75%, more preferably at least about 90%, of the biological activity.
  • Substitutional variants typically exchange one amino acid for another at one or more sites within the protein. Substitutions of this kind can be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions include, for example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.
  • the microorganism comprises an analog or variant of the exogenous or over-expressed polynucleotide(s) described herein.
  • Nucleic acid sequence variants include one or more substitutions, insertions, or deletions, and variants may be substantially homologous or substantially identical to the unmodified polynucleotide.
  • Polynucleotide variants or analogs encode mutant enzymes having at least partial activity of the unmodified enzyme.
  • polynucleotide variants or analogs encode the same amino acid sequence as the unmodified polynucleotide.
  • Codon optimized sequences for example, generally encode the same amino acid sequence as the parent/native sequence but contain codons that are preferentially expressed in a particular host organism.
  • a polypeptide or polynucleotide "derived from” an organism contains one or more modifications to the naturally-occurring amino acid sequence or nucleotide sequence and exhibits similar, if not better, activity compared to the native enzyme (e.g. , at least 70%, at least 80%, at least 90%, at least 95%, at least 100%, or at least 110% the level of activity of the native enzyme).
  • enzyme activity is improved in some contexts by directed evolution of a parent/naturally-occurring sequence.
  • an enzyme coding sequence is mutated to achieve feedback resistance.
  • Expression vectors for recombinant genes can be produced in any suitable manner to establish expression of the genes in a microorganism.
  • Expression vectors include, but are not limited to, plasmids and phage.
  • the expression vector can include the exogenous polynucleotide operably linked to expression elements, such as, for example, promoters, enhancers, ribosome binding sites, operators and activating sequences.
  • expression elements may be regulatable, for example, inducible (via the addition of an inducer).
  • the expression vector can include additional copies of a polynucleotide encoding a native gene product operably linked to expression elements.
  • heterologous promoters include, but are not limited to: the LTR (long terminal 35 repeat from a retrovirus) or SV40 promoter, the E. coli lac, tet, or trp promoter, the phage Lambda PL promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
  • the expression vector also includes appropriate sequences for amplifying expression.
  • the expression vector can comprise elements to facilitate incorporation of polynucleotides into the cellular genome.
  • introduction of the expression vector or other polynucleotides into cells can be performed using any suitable method, such as, for example, transformation, electroporation, microinjection, microprojectile bombardment, calcium phosphate precipitation, modified calcium phosphate precipitation, cationic lipid treatment, photoporation, fusion methodologies, receptor mediated transfer, or polybrene precipitation.
  • the expression vector or other polynucleotides can be introduced by infection with a viral vector, by conjugation, by transduction, or by other suitable methods.
  • Microorganisms of the invention comprising recombinant genes are cultured under conditions appropriate for growth of the cells and expression of the gene(s).
  • Microorganisms expressing the polypeptide(s) can be identified by any suitable methods, such as, for example, by PCR screening, screening by Southern blot analysis, or screening for the expression of the protein.
  • microorganisms that contain the polynucleotide can be selected by including a selectable marker in the DNA construct, with subsequent culturing of
  • microorganisms containing a selectable marker gene under conditions appropriate for survival of only those cells that express the selectable marker gene.
  • the introduced DNA construct can be further amplified by culturing genetically modified microorganisms under appropriate conditions (e.g. , culturing genetically modified microorganisms containing an amplifiable marker gene in the presence of a concentration of a drug at which only microorganisms containing multiple copies of the amplifiable marker gene can survive).
  • the microorganisms (such as genetically modified bacterial cells) have an optimal temperature for growth, such as, for example, a lower temperature than normally encountered for growth and/or fermentation.
  • cells of the invention exhibit a decline in growth at higher temperatures as compared to normal growth and/or fermentation temperatures as typically found in cells of the type.
  • Any cell culture condition appropriate for growing a microorganism and synthesizing a product of interest is suitable for use in the inventive method.
  • the methods of the invention optionally comprise a step of product recovery.
  • acrylate can be recovered by distillation methods, extraction methods, crystallization methods, or combinations thereof; 3-hydroxypropionate can be recovered as described in U.S. Published Patent Application No. 2011/038364 or International Publication No. WO 2011/0125118; polyhydroxyalkanoates can be recovered as described in Yu and Chen, Biotechnol Prog, 22(2): 547-553 (2006); and 1,3 propanediol can be recovered as described in U.S. Patent No. 6428992 or Cho et al. , Process Biotechnology, 41(3): 739-744 (2006).
  • Examples 1 to 6 describe the construction of different plasmids for heterologous expression of proteins in E. coli; Examples 7 and 8 describe the transformation and culture of E. coli strains; Examples 9 and 10 describe the purification of several proteins; Example 12 describes a method for quantification of acyl-CoA molecules; Examples 11 and 13 to 16 describe the in vitro reconstitution of the enzymatic activity of several proteins described in the present invention; Example 17 describe the production of 3- hydroxypropionic acid in engineered E. coli.
  • E. coli expression vectors were constructed for production of recombinant
  • the Xbal site in the lac operator was removed and the region encoding for the thrombin, S-tag and enterokinase sites was replaced for a sequence encoding for a Factor Xa recognition site.
  • the multiple cloning site was modified to include EcoRY, EcoRl, BamHl, Sacl, and Pstl sites.
  • An E. coli expression vector was constructed for production of a recombinant branched- chain 2-keto acid decarboxylase (KdcA).
  • KdcA branched- chain 2-keto acid decarboxylase
  • a Lactococcus lactis branched-chain 2-keto acid decarboxylase gene was codon-optimized for expression in E. coli, and the common restriction sites: Avrll; BamUl; Bglll; BstBl; Eagl; EcoRl; EcoRY; Hindlll; Kpnl; Ncol; Nhel; Notl; NspY; Pstl; Pvull; Sacl; Sail; Sapl; Sful; Spel; Xbal; Xhol were removed to facilitate cloning.
  • An E. coli expression vector was constructed for production of a recombinant coenzyme -
  • a acylating propionaldehyde dehydrogenase (PduP).
  • a Salmonella enterica coenzyme-A acylating propionaldehyde dehydrogenase gene was codon-optimized for expression in E. coli, and the common restriction sites: Avrll; BamUl; Bglll; BstBl; Eagl; EcoRl; EcoRY; Hindlll; Kpnl; Ncol; Nhel; Notl; NspY; Pstl; Pvull; Sad; Sail; Sapl; Sful; Spel; Xbal; Xhol were removed to facilitate cloning.
  • An E. coli expression vector was constructed for production of a recombinant poly (3- hydroxybutyrate) polymerase.
  • a Cupriavidus necator poly (3 -hydroxy butyrate) polymerase (phaC) gene was codon-optimized for expression in E. coli, and the common restriction sites: Avrll; BamUl; Bglll; BstBl; Eagl; EcoRl; EcoRY; Hindlll; Kpnl; Ncol; Nhel; Notl; NspY; Pstl; Pvull; Sacl; Sail; Sapl; Sful; Spel; Xbal; Xhol were removed to facilitate cloning.
  • An E. coli expression vector was constructed for production of a recombinant 3- hydroxypropionyl-CoA dehydratase.
  • a Metallosphaera sedula 3-hydroxypropionyl-CoA dehydratase gene was codon-optimized for expression in E. coli, and the common restriction sites: Avrll; BamUl; Bglll; BstBl; Eagl; EcoRl; EcoRY; Hindlll; Kpnl; Ncol; Nhel; Notl; NspY; Pstl; Pvull; Sad; Sail; Sapl; Sful; Spel; Xbal; Xhol were removed to facilitate cloning.
  • E. coli expression vectors were constructed for production of recombinant short to medium-chain acyl-CoA thioesterases.
  • Thioesterase genes from different organisms were codon- optimized for expression in E. coli, and the common restriction sites: BamHl, Bglll, BstBl, EcoRl, Hindlll, Kpnl, Pstl, Ncol, Notl, Sacl, Sail, Xbal, and Xhol were removed to facilitate cloning.
  • additional BamHl and Xbal restriction sites 5' to the ATG start codon, and Sacl and Hindlll restriction sites 3' to the stop codon were included into the sequence.
  • the recombinant plasmids were then used to transform chemically competent One Shot BL21 (DE3) pLysS E. coli cells (Invitrogen, Carlsbad, CA). Individual vials of cells were thawed on ice and gently mixed with 10 ng of plasmid DNA. The vials were incubated on ice for 30 min. The vials were briefly incubated at 42°C for 30 sec and quickly replaced back on ice for an additional 2 min. An aliquot of 250 ⁇ L of 37°C SOC medium was added and the vials were secured horizontally on a shaking incubator platform and incubated for 1 h at 37 °C, 225 rpm.
  • His-tagged recombinant proteins were isolated by immobilized metal affinity
  • IMAC nickel-nitrilotriacetic acid coupled Sepharose CL-6B resin
  • IMAC nickel-nitrilotriacetic acid coupled Sepharose CL-6B resin
  • Cell pellets were thawed on ice and suspended in 20 mL of binding buffer (20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH 7.4) supplemented with 1 mg/mL lysozyme and 1 pellet of Complete EDTA-free protease inhibitor (Roche Applied Science, Indianapolis, IN) . Samples were incubated at 4°C with 30 rpm rotation for 30 min followed by French-pressing (1000 psi).
  • Bound proteins were eluted by gravity-flow in 10 CV (50 mL) of elution buffer (20 mM sodium phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.4) and collected in fractions. Elution aliquots were assayed for protein content by SDS-PAGE analysis, pooled, and concentrated with Amicon Ultra- 15 centrifugal filter devices (EMD Millipore, Billerica, MA) with 30 kDa nominal molecular weight cut-off.
  • EMD Millipore Billerica, MA
  • the concentrated protein isolates were desalted and eluted into 3.5 mL of storage buffer (50 mM HEPES, 300 mM NaCl, 20% glycerol, pH 7.3) using PD-10 desalting columns (GE Healthcare Biosciences, Pittsburgh, PA).
  • His-tagged recombinant thioesterases were isolated by IMAC utilizing sepharose based magnetic beads with nickel ions (His Mag Sepharose Ni) as follows. Cell pellets were thawed at room temperature and suspended in 1.7 mL of IX BugBuster (primary amine free; with ⁇ /mL Benzonase nuclease; Novagen # 70923-3 and 70750-3 respectively). Samples were incubated at room temperature with 60 rpm rotation for 30 min. Cell debris was pelleted by centrifugation for 10 min at 14,000 rpm. The supernatants were transferred to His Mag Sepharose Ni (GE
  • the recombinant thioesterases were eluted from the beads in 300 ⁇ L ⁇ of elution buffer (20 mM sodium phosphate, 500 mM NaCl, 500 mM imidazole, pH 7.4) by slow end-over-end mixing for 5 min.
  • the purified recombinant proteins were assayed spectrophotometrically in a series of coupled enzyme reactions.
  • Pf AT aminotransferase was added at 0.27 mg/ml final concentration to 100 mM potassium phosphate buffer (pH 8.0; Sigma, St. Louis, MO).
  • L- Homoserine Sigma, St. Louis, MO; catalog # H6515
  • L- Valine Sigma, St. Louis, MO;
  • NADH ⁇ -nicotinamide adenine dinucleotide
  • N8410 ⁇ - Nicotinamide adenine dinucleotide
  • Pyroxidal 5 '-phosphate hydrate (Sigma, St. Louis, MO; catalog # P9255) was added at 50 ⁇ final concentration.
  • oc-Ketoglutaric acid, disodium salt, dehydrate (Sigma, St. Louis, MO; catalog # 75892) was added as a secondary substrate at 1 mM final concentration.
  • L-Glutamic dehydrogenase from bovine liver (Sigma, St. Louis, MO; catalog # G2626) was added at 10 U/mL. Each reaction was added to a 1 mL quartz cuvette and the formation of NADH was followed over time at 340 nm in a spectrophotometer. As expected, the initial rate of conversion of L-homoserine was dependent on its concentration (Figure 5).
  • a stable-labeled (deuterium) internal standard-containing master mix comprising d3-3-hydroxymethylglutaryl-CoA (200 ⁇ L ⁇ of 50 ⁇ g/mL stock in 10 mL of 15% trichloroacetic acid).
  • An aliquot (500 ⁇ ) of the master mix is added to a 2-mL tube.
  • Silicone oil (AR200; Sigma, St. Louis, MO; catalog # 85419; 800 ⁇ ) is layered onto the master mix.
  • An aliquot of E. coli culture (800 ⁇ ) is layered gently on top of the silicone oil.
  • the sample is subject to centrifugation at 20,000 x g for 5 min at 4°C in an Eppendorf 5417C centrifuge.
  • An aliquot (300 ⁇ ) of the master mix-containing layer is transferred to an empty tube and frozen on dry ice for 30 min.
  • acyl-CoA content of samples was determined using LC-MS/MS. Individual acyl-CoA content of samples was determined using LC-MS/MS. Individual acyl-CoA content of samples was determined using LC-MS/MS. Individual acyl-CoA content of samples was determined using LC-MS/MS. Individual acyl-CoA content of samples was determined using LC-MS/MS. Individual acyl-CoA content of samples was determined using LC-MS/MS. Individual acyl-
  • CoA standards were purchased from Sigma (St. Louis, MO) and prepared as 500 ⁇ g/mL stocks in methanol. Acryloyl-CoA was synthesized and prepared similarly. The analytes were pooled, and standards with all of the analytes were prepared by dilution with 15% trichloroacetic acid. Standards for regression were prepared by transferring 500 ⁇ L ⁇ of the working standards to an autosampler vial containing 10 ⁇ L ⁇ of the 50 ⁇ g/mL internal standard. Sample peak areas (or heights) were normalized to the stable-labeled internal standard (d 3 -3-hydroxymethylglutaryl- CoA).
  • the conditions on the mass spectrometer were: DP 160, CUR 30, GS1 65, GS2 65, IS 4500, CAD 7, TEMP 650 C.
  • the transitions used for the multiple reaction monitoring were: DP 160, CUR 30, GS1 65, GS2 65, IS 4500, CAD 7, TEMP 650 C.
  • D-homoserine (2 mM; Acros, Geel, Belgium; catalog # 348362500) was incubated with D-amino acid oxidase (1 U/mL; Sigma, St. Louis, MO; catalog # A5222) and bovine liver catalase (600 U/mL; Sigma, St. Louis, MO; catalog # C40) in the presence of HEPES buffer (50 mM, pH 7.3).
  • D-homoserine (2 mM; Acros, Geel, Belgium; catalog # 348362500) was incubated with D-amino acid oxidase (1 U/mL; Sigma, St. Louis, MO; catalog # A5222) and bovine liver catalase (600 U/mL; Sigma, St. Louis, MO; catalog # C40) in the presence of HEPES buffer (50 mM, pH 7.3).
  • HPLC HPLC chromatography
  • Agilent 1100 Agilent 1100 system
  • Agilent 1100 Agilent 1100
  • Waters Atlantis T3 column Waters, Milford, MA; catalog # 186003748
  • Mobile phases were 0.1% phosphoric acid in water (A) and 0.1% phosphoric acid in 80% acetonitrile / 20% water (B).
  • Analytes were eluted isocratically at 2% B in A over 12 min, followed by a linear gradient from 2% to 35% B in A over 18 min.
  • the HPLC analysis indicates consumption of acryloyl-CoA and formation of a different absorbing molecule (Figure 7).
  • the identity of the reaction product, 3-hydroxypropionyl-CoA was confirmed by LC-MS analysis as described in example 12 ( Figure 8).
  • Ellman's reagent also known as DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)
  • the assay buffer was 50 mM KC1, 10 mM HEPES (pH 7.4).
  • a lOmM Ellman's reagent stock solution was prepared in ethanol.
  • An acryloyl-CoA substrate stock solution was prepared to 10 mM in assay buffer.
  • the reaction was as follows: a lOmM Ellman's reagent stock solution was diluted to a 50 ⁇ final concentration in assay buffer. Acryloyl-CoA stock solution was added to provide a 90 ⁇ final concentration. The Ellman's reagent/acryloyl- CoA mixture (95 ⁇ per well) was added to a 96-well polystyrene untreated microtiter plate. Equivalent reactions with no substrate were prepared as controls. Purified enzyme was serially diluted 1:3 in assay buffer in a separate plate, and 5 ⁇ was added to a reaction well.
  • Thioesterase activity was assessed at 60 min by measuring the optical density (OD) at 412 nm on a plate reader. Relative enzyme activities were calculated by subtracting OD (412 nm) of substrate-free controls from OD (412 nm) of substrate-containing samples.
  • EcTesB and CpTT showed acryloyl-CoA thioesterase activity in the assay based on generation of a free sulfhydryl from the acryloyl-CoA. As a further test of this thioesterase activity, it is useful to observe the disappearance of substrate and appearance of product.
  • LC-MS was used to monitor substrate and product amounts in assays with these enzymes as described in Example 12.
  • the amount of EcTesB correlates with the increase in acryloyl-CoA hydrolysis, as indicated by both the detection of Coenzyme A by Ellman' s reagent and by the disappearance of acryloyl-CoA (Table 1).
  • the enzyme is diluted, the thioesterase activity levels decline, as indicated by each assay.
  • EcTesB and CpTT each show acryloyl-CoA hydrolysis activity by two different assays (Table 6). Each enzyme causes in increase in coenzyme A, as detected with Ellman' s reagent.
  • Each enzyme also causes a changing profile in the LC-MS analysis, with the thioesterases causing a decrease in acryloyl-CoA and an increase in coenzyme A (Table 6).
  • This example demonstrates increased production of 3-hydroxypropionic acid in E. coli host cells which can then be converted to poly- 3-hydroxypropionic acid or acylic acid.
  • E. coli strains were established to overexpress P. fluorescens branched-chain amino acid
  • PduP propionaldehyde dehydrogenase
  • PhaC Poly(3 -hydroxybutyrate) polymerase
  • P. fluorescens branched-chain amino acid aminotransferase (SEQ ID NO: 8) promoted the conversion of L-homoserine to 2-keto-4-hydroxybutyrate.
  • the L. lactis branched-chain 2-keto acid decarboxylase (KdcA, set out in SEQ ID NO: 540 catalyzed the conversion of 2-keto-4-hydroxybutyrate to 3-hydroxy-propionaldehyde.
  • the S. enterica coenzyme-A acylating propionaldehyde dehydrogenase (PduP, set out in SEQ ID NO: 60) catalyzed the conversion of 3-hydroxy-propionaldehyde to 3-hydroxypropionyl-CoA.
  • a thioesterase catalyzed the conversion of 3-hydroxypropionyl-CoA to 3-hydroxypropionate.
  • the C. necator Poly (3-hydroxybutyrate) polymerase (PhaC, set out in SEQ ID NO: 42) can catalyze the conversion of 3-hydroxypropionyl-CoA to poly-3-hydroxypropionate.
  • An E. coli expression vector was constructed for overexpression of a recombinant
  • the Cn PHAS fragment was band isolated, purified using a QIAquick Gel Extraction Kit (Qiagen, Carlsbad, CA) and ligated (Fast-Link Epicentre Biotechnologies, Madison, WI) with 5/? ⁇ ? I PsiI-digested pET30a-BB Pf AT vector.
  • the ligation mix was used to transform OneShot ToplOTM E. coli cells (Invitrogen, Carlsbad, CA).
  • the recombinant plasmid was isolated using a Qiagen Plasmid Mini Kit and characterized by gel electrophoresis of restriction digests with ⁇ / ⁇ .
  • the resulting plasmid was designated pET30a-BB PfAT_Cn PHAS.
  • An E. coli expression vector was constructed for overexpression of a recombinant S. enterica coenzyme-A acylating propionaldehyde dehydrogenase (PduP) and L. lactis branched- chain 2-keto acid decarboxylase (KdcA).
  • the codon optimized L. lactis branched-chain 2-keto acid decarboxylase (kdcA) from pET30a-BB LI KDCA (Example 2) was cloned into pET30a-BB Se PDUP (Example 3) by double digestion of pET30a-BB LI KDCA with restriction enzymes Xbal and Pstl.
  • the LI KDCA fragment was band isolated, purified using a QIAquick Gel Extraction Kit (Qiagen, Carlsbad, CA) and ligated (Fast-Link Epicentre Biotechnologies, Madison, WI) with Spel/Pstl-digested pET30a-BB Se PDUP vector.
  • the ligation mix was used to transform OneShot ToplOTM E. coli cells (Invitrogen, Carlsbad, CA).
  • Individual vials of cells were thawed on ice and gently mixed with 2 ⁇ L ⁇ of ligation mix. The vials were incubated on ice for 30 min. The vials were briefly incubated at 42°C for 30 sec and quickly replaced back on ice for an additional 2 min. 250 ⁇ L ⁇ of 37°C SOC medium was added and the vials were secured horizontally on a shaking incubator platform and incubated for 1 h at 37 °C and 225 rpm.
  • the codon optimized S. enterica coenzyme-A acylating propionaldehyde dehydrogenase (pduP) and L. lactis Branched-chain 2-keto acid decarboxylase (kdcA) gene pair was subcloned from pET30a-BB Se PDUP_Zi KDCA into the pCDFDuet-1 vector (Novagen, EMD Chemicals, Gibbstown, NJ; catalog # 71340-3) by double digestion of pET30a-BB Se PDUP_Zi KDCA with restriction enzymes EcoRl and Pstl.
  • the Se PDUP_L/ KDCA fragment was band isolated, purified using a QIAquick Gel Extraction Kit (Qiagen, Carlsbad, CA) and ligated (Fast-Link Epicentre Biotechnologies, Madison, WI) with EcoRI/Psil-digested pCDFDuet-1.
  • the ligation mix was used to transform OneShot Top 10TM E. coli cells (Invitrogen, Carlsbad, CA).
  • Individual vials of cells were thawed on ice and gently mixed with 2 ⁇ of ligation mix. The vials were incubated on ice for 30 min. The vials were briefly incubated at 42°C for 30 sec and quickly replaced back on ice for an additional 2 min.
  • the recombinant plasmids and empty parent vectors were used to co-transform chemically competent BL21 (DE3) pLysS E. coli cells (Invitrogen, Carlsbad, CA) in the following combinations:
  • E. coli BL21 (DE3) pLysS cells co-transformed with the described plasmids were used to inoculated aliquots of minimal M9 broth (25 mL) supplemented with the appropriate antibiotics (34 ⁇ g/mL chloramphenicol, 50 ⁇ g/mL kanamycin, and 50 ⁇ g/mL spectinomycin). The cultures were incubated overnight at 37°C with shaking at 250 rpm and used to inoculated fresh minimal M9 media (50 mL) supplemented with the same antibiotics.
  • antibiotics 34 ⁇ g/mL chloramphenicol, 50 ⁇ g/mL kanamycin, and 50 ⁇ g/mL spectinomycin.
  • the LC separation conditions were as follows: 10 ⁇ of sample/standard were injected onto a Thermo Fisher Dionex ICE- AS 1 (4x250 mm) column (with guard) running an isocratic mobile phase of 1 mM heptafluorbutyric acid at a flow rate of 0.15 mL/min. 20 mM NH 4 OH in MeCN at 0.15 mL/min was teed into the column effluent.
  • the MS detection conditions were as follows: A Sciex API-4000 MS was run in negative ion mode and monitored the m/z 89 to 59 (unit resolution) transition of 3-hydroxypropanoic acid and the m/z 92 to 45 (unit resolution) transition of 13 C 3 -labelled lactic acid.
  • the dwell time used was 300 ms
  • the declustering potential was set at -38
  • the entrance potential was set at -10
  • the collision gas was set at 12
  • the curtain gas was set at 15
  • the ion source gas 1 was set at 55
  • the ion source gas 2 was set at 55
  • the ionspray voltage was set at -3500
  • the temperature was set at 650
  • the interface heater was on.
  • the collision energy was set at -16 and the collision set exit potential was set at -9.
  • 13 C 3 -labelled lactic acid the collision energy was set at -18 and the collision set exit potential was set at -16.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne des microorganismes qui convertissent une source de carbone en acrylate ou autres produits souhaitables à l'aide d'homosérine et de 2-céto-4-hydroxybutyrate comme intermédiaires. L'invention porte sur des microorganismes génétiquement modifiés qui effectuent la conversion, ainsi que sur des procédés de production d'acrylate par culture des microorganismes. L'invention concerne également des microorganismes et des procédés de conversion d'homosérine en 3-hydroxypropionyl-CoA, 3-hydroxypropionate (3HP), poly-3-hydroxypropionate et 1,3-propanediol.
EP12780579.4A 2011-10-05 2012-10-05 Microorganismes et procédés de production d'acrylate et autres produits à l'aide d'homosérine Withdrawn EP2764111A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543511P 2011-10-05 2011-10-05
PCT/US2012/058826 WO2013052717A2 (fr) 2011-10-05 2012-10-05 Microorganismes et procédés de production d'acrylate et autres produits à l'aide d'homosérine

Publications (1)

Publication Number Publication Date
EP2764111A2 true EP2764111A2 (fr) 2014-08-13

Family

ID=47116373

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12780579.4A Withdrawn EP2764111A2 (fr) 2011-10-05 2012-10-05 Microorganismes et procédés de production d'acrylate et autres produits à l'aide d'homosérine

Country Status (5)

Country Link
EP (1) EP2764111A2 (fr)
CN (1) CN103890186A (fr)
AU (1) AU2012318597A1 (fr)
CA (1) CA2849823A1 (fr)
WO (1) WO2013052717A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102266181B1 (ko) 2013-09-03 2021-06-17 피티티 글로벌 케미컬 퍼블릭 컴퍼니 리미티드 1,3-프로판디올로부터 아크릴산, 아크릴로니트릴 및 1,4-부탄디올의 제조방법
EP2930244A1 (fr) * 2014-04-07 2015-10-14 The Procter and Gamble Company Micro-organismes et procédés de production d'acrylate et d'autres produits à partir d'homosérine
US20190233853A1 (en) * 2018-02-01 2019-08-01 Invista North America S.A.R.L. Methods and materials for the biosynthesis of beta hydroxy acids and/or derivatives thereof and/or compounds related thereto
CN110777127A (zh) * 2019-11-28 2020-02-11 江南大学 一种支链氨基酸转氨酶作为还原酶的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801058B1 (fr) 1999-11-16 2002-01-18 Roquette Freres Procede de purification du 1,3-propanediol a partir d'un milieu de fermentation
JP4780961B2 (ja) * 2002-05-10 2011-09-28 メタボリックス，インコーポレイテッド ２−ヒドロキシ酸モノマーを含む生体吸収性ポリマー
DE102005048818A1 (de) * 2005-10-10 2007-04-12 Degussa Ag Mikrobiologische Herstellung von 3-Hydroxypropionsäure
TWI456949B (zh) 2008-04-30 2014-10-11 Thomson Licensing 閘口裝置及其使用方法
BRPI0923748B1 (pt) * 2008-12-31 2019-04-09 Metabolic Explorer Método para a preparação de dióis
WO2010085731A2 (fr) 2009-01-23 2010-07-29 Microbia, Inc. Production de 1,4-butanediol dans un microorganisme
DE102009035091A1 (de) 2009-07-28 2011-02-10 Mahle International Gmbh Positionssensor und Linearaktuator
CA2781400A1 (fr) 2009-11-20 2011-05-26 Opx Biotechnologies, Inc. Production d'un acide organique, et/ou produits chimiques connexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013052717A2 *

Also Published As

Publication number Publication date
WO2013052717A2 (fr) 2013-04-11
AU2012318597A2 (en) 2014-11-06
AU2012318597A1 (en) 2014-04-24
CA2849823A1 (fr) 2013-04-11
CN103890186A (zh) 2014-06-25
WO2013052717A3 (fr) 2013-06-13

Similar Documents

Publication Publication Date Title
US20240191216A1 (en) Recombinant host cells for the production of malonate
KR102093172B1 (ko) 2,4-다이하이드록시부티레이트의 제조 방법
EP3490969A1 (fr) N-acétyl homosérine
WO2013052717A2 (fr) Microorganismes et procédés de production d'acrylate et autres produits à l'aide d'homosérine
US20140099676A1 (en) Microorganisms and methods for producing acrylate and other products from homoserine
KR101521045B1 (ko) 유기산을 생산하기 위한 재조합 미생물유기체
US20140296571A1 (en) Microorganisms And Methods For Producing Propionic Acid
KR20220021436A (ko) 고알칼리 조건에서 활성이 높은 신규 라이신 디카르복실라제 및 이를 이용한 카다베린 생산 방법
JP5707318B2 (ja) Ｌ−リシン生産の方法
WO2021050348A1 (fr) Activité de la peroxydase envers la 10-acétyl -3,7-dihydroxyphénoxazine
WO2015031504A1 (fr) Voie et organismes recombinés pour la synthèse de la malonyl-coenzyme a
CN111406104B (zh) 减少为了生产氨基酸或氨基酸衍生产物的亚胺/烯胺的积累
US20140107377A1 (en) Microorganisms And Methods For Producing Acrylate And Other Products From Propionyl-CoA
RU2706535C2 (ru) Микроорганизм, продуцирующий O-ацетилгомосерин, и способ получения O-ацетилгомосерина с использованием этого микроорганизма
US20200224228A1 (en) Novel o-succinyl homoserine transferase mutant and method for producing o-succinyl homoserine using same
KR101725454B1 (ko) 하프니아 알베이 유래의 라이신 디카르복실라아제를 코딩하는 유전자, 이를 포함하는 재조합 벡터, 숙주세포 및 이를 이용한 카다베린의 생산방법
US11708564B2 (en) Microorganism expressing active D-proline reductase and method of producing active D-proline reductase
EP3489361B1 (fr) Micro-organisme ayant une activité d'acyltransférase et son utilisation
EP2930244A1 (fr) Micro-organismes et procédés de production d'acrylate et d'autres produits à partir d'homosérine
EP3694989A1 (fr) Phosphosérine aminotransférase mutante destinée à la conversion d'homosérine en 4-hydroxy-2-cétobutyrate
RU2811433C1 (ru) Новый полипептид и способ получения l-лейцина с его использованием
WO2022210228A1 (fr) SYNTHASE D'α-ISOPROPYLMALATE MODIFIÉE
AU2021306531A1 (en) Modified glutamate dehydrogenase and use thereof
WO2024054828A2 (fr) Cellules hôtes recombinées pour la production de malonate
JP2023503218A (ja) アセトヒドロキシ酸シンターゼ新規変異体及びこれを含む微生物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140415

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503